Celgene to stop testing Crohn's drug, shares drop

(Reuters) - Celgene Corp said it would abandon testing a drug to treat Crohn's disease, an inflammatory bowel disease, following a risk-benefit analysis by a data monitoring committee, in a major setback to the drugmaker's pipeline.